Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck.
Overview
abstract
This commentary highlights the article by Parikh and colleagues, regarding biweekly therapy with the anti-EGFR monoclonal antibody, cetuximab, for gastrointestinal cancer.
